The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept
Authors:
- 1 December 2011
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 36 (8) , 845-850
Abstract
Psoriasis is a chronic, systemic, inflammatory disease. Inflammatory markers are used in clinical practice to detect acute inflammation, and as markers of treatment response. Etanercept blocks tumour necrosis factor (TNF)-α, which plays a central role in the psoriatic inflammation process. To reveal any possible association between disease severity [measured by Psoriasis Area and Severity Index (PASI)] and the inflammatory burden (measured by a group of inflammatory markers), before and after etanercept treatment. In total, 41 patients with psoriasis vulgaris, eligible for biological treatment with etanercept, were enrolled in the study. A set of inflammatory markers was measured, including levels of white blood cells and neutrophils, fibrinogen, ferritin, high-sensitivity C-reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR), haptoglobin, ceruloplasmin and α1-antitrypsin, before and after 12 weeks of etanercept 50 mg twice weekly. All markers were reduced after treatment (P < 0.001). PASI correlated with fibrinogen and hs-CRP. Of the 41 patients, 19 (46.3%) achieved reduction of 75% in PASI (PASI75). An increase in hs-CRP and ESR difference (values before minus values after treatment) was related to higher likelihood of achieving PASI75. Inflammatory markers, particularly hs-CRP and to a lesser extent, fibrinogen and ESR, can be used to assist in assessing disease severity and response to treatment in patients with psoriasis. A combination of selected inflammatory factors (which we term the Index of Psoriasis Inflammation) in combination with PASI might reflect inflammatory status in psoriasis more accurately than each one separately.Keywords
This publication has 12 references indexed in Scilit:
- British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009British Journal of Dermatology, 2009
- European S3‐Guidelines on the systemic treatment of psoriasis vulgarisJournal of the European Academy of Dermatology and Venereology, 2009
- A comprehensive review of biomarkers in psoriasisClinical and Experimental Dermatology, 2009
- Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approachBritish Journal of Dermatology, 2008
- Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritisBritish Journal of Dermatology, 2008
- Pathogenesis and clinical features of psoriasisThe Lancet, 2007
- Cracking the cytokine code in psoriasisNature Medicine, 2007
- Pathogenesis and therapy of psoriasisNature, 2007
- Risk of Myocardial Infarction in Patients With PsoriasisJAMA, 2006
- The inflammatory response in mild and in severe psoriasisBritish Journal of Dermatology, 2004